- Home
- NAGE vs ARMP Comparison
NAGE vs ARMP Comparison
Compare NAGE & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | ARMP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.8M | 383.7M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NAGE | ARMP |
|---|---|---|
| Price | $4.96 | $11.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.00 | $15.00 |
| AVG Volume (30 Days) | ★ 631.9K | 49.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.16 | $1.17 |
| 52 Week High | $14.66 | $14.98 |
Technical Indicators
Market Signals| Indicator | NAGE | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 48.53 |
| Support Level | $4.73 | $5.14 |
| Resistance Level | $5.32 | $12.11 |
| Average True Range (ATR) | 0.18 | 1.40 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 85.11 | 30.02 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.